The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer.
Sinhan Tran
Employment or Leadership Position - Ludwig Institute for Cancer Research
Neal Ready
No relevant relationships to disclose
Lee M. Krug
No relevant relationships to disclose
Maria Catherine Pietanza
Research Funding - Merck
Achim A Jungbluth
Employment or Leadership Position - Ludwig Institute for Cancer Research
Linda S. Pan
Employment or Leadership Position - Ludwig Institute for Cancer Research
Ralph Rudolph Venhaus
Employment or Leadership Position - Ludwig Institute for Cancer Research
Eric W. Hoffman
Employment or Leadership Position - Ludwig Institute for Cancer Research
Honoraria - Polaris
Ann-Marie Peters
No relevant relationships to disclose
Karen Dukelow
No relevant relationships to disclose
John S. Bomalaski
Employment or Leadership Position - Polaris Group
Bor-Wen Wu
Employment or Leadership Position - Polaris Group
Stock Ownership - Polaris Group
Lloyd J. Old
Employment or Leadership Position - Ludwig Institute for Cancer Research (U)